Securin as a Prognostic Marker in Breast Cancer
Author Information
Author(s): Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, Kronqvist P
Primary Institution: Turku University Hospital, University of Turku
Hypothesis
Can securin serve as a reliable proliferation marker in invasive ductal breast cancer?
Conclusion
Securin immunostaining is a promising and clinically applicable proliferation marker that may help identify patients with a more favorable prognosis in invasive ductal breast cancer.
Supporting Evidence
- Securin expression was significantly altered in invasive ductal breast cancer.
- Low securin expression was associated with a more favorable prognosis.
- Securin immunostaining showed a different stratification of breast cancer cases compared to traditional markers.
Takeaway
Securin is a protein that helps doctors understand how aggressive a breast cancer is, and low levels of it can mean a better chance of recovery.
Methodology
The study used cDNA microarrays and immunohistochemistry to analyze securin expression in breast cancer samples.
Potential Biases
Potential biases may arise from the small sample size and the reliance on specific cutoff points for immunohistochemical evaluations.
Limitations
The study had a small sample size and relatively short follow-up time.
Participant Demographics
Patients diagnosed with invasive ductal breast cancer, with a mean age of 63 years.
Statistical Information
P-Value
0.0270
Confidence Interval
1.3–40.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website